New cancer drug saruparib enters early human testing
NCT ID NCT06899061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions work. This study is not designed to cure cancer but to gather important information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Saruparib (a drug taken by mouth)
What this could lead to
If successful, this trial could help determine the right dose of saruparib and how it interacts with other drugs, potentially leading to better treatment options for advanced solid tumors.
What could go wrong
This is a very early (Phase 1) study with only 41 participants. It primarily looks at drug levels and safety, not whether the drug shrinks tumors. Many early-stage drugs do not advance to become treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sofia, 1618, Bulgaria
-
Research Site
Chisinau, MD-2025, Moldova
-
Research Site
Bucharest, 022338, Romania
-
Research Site
Cluj-Napoca, 400015, Romania